112 assets in Nonpapillary Renal Cell Carcinoma

Therapeutic assets addressing Nonpapillary Renal Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ceralasertib Nonpapillary Renal Cell Carcinoma	Rahul Aggarwal	P2	CCC (51)
Fianlimab Nonpapillary Renal Cell Carcinoma	Brian Rini	P2	CCC (51)
Ivuxolimab Nonpapillary Renal Cell Carcinoma	University of Southern California	P2	CCC (51)
Olaparib Nonpapillary Renal Cell Carcinoma	Rahul Aggarwal	P2	CCC (51)
Slc-3010 Nonpapillary Renal Cell Carcinoma	Yonsei University	P2	CCC (51)
Tifcemalimab Nonpapillary Renal Cell Carcinoma	Fudan University	P2	CCC (51)
Adavosertib Nonpapillary Renal Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (50)
[177lu]lu-dpi-4452 Nonpapillary Renal Cell Carcinoma	ITM Oncologics GmbH	P1/2	CCC (48)
[68ga]ga-dpi-4452 Nonpapillary Renal Cell Carcinoma	ITM Oncologics GmbH	P1/2	CCC (48)
AB-2100 Nonpapillary Renal Cell Carcinoma	Arsenal Biosciences, Inc.	P1/2	CCC (48)
Avelumab Nonpapillary Renal Cell Carcinoma	Bradley A. McGregor, MD	P2	CCC (48)
EB-701 Nonpapillary Renal Cell Carcinoma	Beijing Biotech	P1/2	CCC (48)
eb-701/ca9-nk Nonpapillary Renal Cell Carcinoma	Beijing Biotech	P1/2	CCC (48)
gi-101a Nonpapillary Renal Cell Carcinoma	GI Innovation, Inc.	P1/2	CCC (48)
Human T-Lymphocyte Activation Antigen Cd80 (Activation B7-1 Antigen, Ctla-4 Counter-Receptor B7.1, Cd80) Extracellular Domain Containing Fragment (1-208 In The Current Sequence) Fused Via Peptide Linker <Sup>209</Sup>Gsggggsggggsggggs<Sup>225</Sup> To An Fc Fragment Of Human Immunoglobulin G4 (226-454) [Homo Sapiens Ighg4*01, Hinge Ins<Sup>226</Sup>>A, S<Sup>236</Sup>>P (226-238), Ch2 F<Sup>242</Sup>>A, L<Sup>243</Sup>>A, T<Sup>258</Sup>>Q (239-348), Ch3 M<Sup>436</Sup>>L (349-453), Chs K<Sup>455</Sup>>Del (454)] Fused Via Peptide/ Linker <Sup>455</Sup>Ggggs<Sup>459</Sup> To Human Interleukin-2 (Il-2, T-Cell Growth Factor (Tcgf)) (1-133, 460-592 In The Current Sequence), Variant (R<Sup>38</Sup>>A<Sup>497</Sup>, F<Sup>42</Sup>>A<Sup>501</Sup>), Dimer (234-234', 237-237')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa Nonpapillary Renal Cell Carcinoma	GI Innovation, Inc.	P1/2	CCC (48)
Lutetium (<Sup>177</Sup>Lu) Zadavotide Guraxetan Nonpapillary Renal Cell Carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P1/2	CCC (48)
Regn15505 Nonpapillary Renal Cell Carcinoma	Regeneron Pharmaceuticals	P1/2	CC (47)
Regn4336 Nonpapillary Renal Cell Carcinoma	Regeneron Pharmaceuticals	P1/2	CC (47)
Xmab808 Nonpapillary Renal Cell Carcinoma	Xencor, Inc.	P1	CC (47)
ctx131 Nonpapillary Renal Cell Carcinoma	CRISPR Therapeutics AG	P1/2	CC (46)
hs-10516 Nonpapillary Renal Cell Carcinoma	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P1/2	CC (45)
Nezastomig Nonpapillary Renal Cell Carcinoma	Regeneron Pharmaceuticals	P1/2	CC (45)
[68ga]ga-oncocaix Nonpapillary Renal Cell Carcinoma	Philogen S.p.A.	P1	CC (44)
18f-trx Nonpapillary Renal Cell Carcinoma	Rahul Aggarwal	P1	CC (43)
23me-00610 Nonpapillary Renal Cell Carcinoma	23andMe, Inc.	P1/2	CC (43)
Adagrasib Nonpapillary Renal Cell Carcinoma	Kura Oncology, Inc.	P1	CC (43)
Adi-270 Nonpapillary Renal Cell Carcinoma	Adicet Therapeutics	P1/2	CC (43)
Allo-316 Nonpapillary Renal Cell Carcinoma	Allogene Therapeutics	P1	CC (43)
Allo-647 Nonpapillary Renal Cell Carcinoma	Allogene Therapeutics	P1	CC (43)
Atezolizumab Nonpapillary Renal Cell Carcinoma	Genentech, Inc.	P1	CC (43)
ca9hu-1 Nonpapillary Renal Cell Carcinoma	Mabpro, a.s.	P1	CC (43)
Darlifarnib Nonpapillary Renal Cell Carcinoma	Kura Oncology, Inc.	P1	CC (43)
Entinostat Nonpapillary Renal Cell Carcinoma	National Cancer Institute (NCI)	P1/2	CC (43)
Guadecitabine Nonpapillary Renal Cell Carcinoma	Ajjai Alva, MD	P1/2	CC (43)
H-Gamma1 Heavy Chain Humanized (1-449) [Vh (Homo Sapiens Ighv3-2301 (81.6%) -(Ighd) -Ighj302 (91.7%) M123>T (114), Cdr-Imgt [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo Sapiens Ighg103V (100%) G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14 (Ch1 R120>K (216) (120-217), Hinge 1-15 (218-232), Ch2 (233-342), Ch3 E12 (358), M14 (360) (343-447), Chs (448-449)) (120-449)], (222-218')-Disulfide With L-Kappa Light Chain Humanized (1'-218') [Vkappa (Homo Sapiens Igkv1-3301 (87.8%) -Igkj401 (100%), Cdr-Imgt [6.3.13] (27'-32'.50'-52'.89'-101')) (1'-111')-Homo Sapiens Igkc01 (100%) Km3 A45.1, V101 (C-Kappaa45.1 (157'), V101 (195')) (112'-218')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa Nonpapillary Renal Cell Carcinoma	Genentech, Inc.	P1	CC (43)
jk08 Nonpapillary Renal Cell Carcinoma	Salubris Biotherapeutics Inc	P1/2	CC (43)
Mdna11 Nonpapillary Renal Cell Carcinoma	Medicenna Therapeutics, Inc.	P1/2	CC (43)
pf-08634404 Nonpapillary Renal Cell Carcinoma	Pfizer	P1/2	CC (43)
Valemetostat Nonpapillary Renal Cell Carcinoma	M.D. Anderson Cancer Center	P1	CC (43)
177Lu-NYM096 Nonpapillary Renal Cell Carcinoma	Peking Union Medical College Hospital	P1	C (39)
[18f]pt2385 Nonpapillary Renal Cell Carcinoma	Orhan Kemal Oz	P1	C (39)
68Ga-NYM096 Nonpapillary Renal Cell Carcinoma	Peking Union Medical College Hospital	P1	C (39)
Bdc-3042 Nonpapillary Renal Cell Carcinoma	Bolt Biotherapeutics, Inc.	P1	C (39)
Clear Car-T Cell Nonpapillary Renal Cell Carcinoma	Chinese PLA General Hospital	Early P1	C (39)
hc-7366 Nonpapillary Renal Cell Carcinoma	HiberCell, Inc.	P1	C (39)
MGC026 Nonpapillary Renal Cell Carcinoma	MacroGenics	P1	C (39)
Myrciaria Dubia Prebiotic Supplement Nonpapillary Renal Cell Carcinoma	City of Hope Medical Center	P1	C (39)
Neo-811 Nonpapillary Renal Cell Carcinoma	Neomorph, Inc	P1	C (39)
nn3201 Nonpapillary Renal Cell Carcinoma	Novelty Nobility, Inc.	P1	C (39)
Sasanlimab Nonpapillary Renal Cell Carcinoma	Stephanie Berg	P2	C (39)

Showing 51 to 100 of 112 assets

PreviousPage 2 of 3Next